Work

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

Year: 2013

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-013-0029-6

Authors: William R. Schelman, Anne M. Traynor, Kyle D. Holen, Jill M. Kolesar, Steven Attia, Tien Hoang, Jens Eickhoff, Zhisheng Jiang, Dona Alberti, Rebecca Marnocha, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Igor Espinoza-Delgado, John J. Wright, George Wilding, Howard H. Bailey

Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), National Institutes of Health, National Cancer Institute

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center, National Institutes of Health, U.S. Public Health Service, Takeda Oncology, National Cancer Institute, National Center for Research Resources, National Center for Advancing Translational Sciences

Awards: Institutional Clinical and Translational Science Award (UW-Madison)(UL1), Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics, Institutional Clinical and Translational Science Award, G6567765281, Phase I Clinical Trials of Anticancer Agents, Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01), Mayo Clinic Comprehensive Cancer Center Support Grant, UW Comprehensive Cancer Center Support

OpenAlex ID: W2009823821

FWCI: 1.791

Cites: 38

Cited by: 28

Related to: 10